| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT06910072 Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and… |
Enrolling by invitation only |
| 2026-08-14 | NCT06910072 Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and… |
date change Primary completion pushed: 2026-10-01 -> 2027-06-01 |
| 2026-08-09 | NCT06403709 Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients |
overall status: Active, Not Recruiting → Unknown |
| 2026-08-09 | NCT05970302 XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC |
overall status: Recruiting → Unknown |
| 2026-08-02 | NCT06509490 NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors |
overall status: Recruiting → Unknown |
| 2026-08-02 | NCT06492629 Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral… |
overall status: Active, Not Recruiting → Unknown |
| 2026-08-02 | NCT06490081 Trilaciclib Prevents Myelosuppression With Chemoradiotherapy |
overall status: Recruiting → Unknown |
| 2026-08-02 | NCT05504265 Perioperative Analgesia Modes in Minimally Invasive Esophagectomy |
overall status: Recruiting → Unknown |
| 2026-07-29 | NCT06417892 Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line… |
date change Primary completion pushed: 2026-05-31 -> 2027-05-31 |
| 2026-07-29 | NCT06417892 Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line… |
date change Completion pushed: 2026-12-30 -> 2027-12-30 |
| 2026-07-25 | NCT07373899 Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After… |
overall status: Not Yet Recruiting → Enrolling by Invitation |
| 2026-07-25 | NCT06038461 An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1… |
date change Primary completion pushed: 2026-09-15 -> 2027-09-15 |
| 2026-07-25 | NCT06038461 An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1… |
date change Completion pushed: 2026-09-15 -> 2028-09-15 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-12 | NCT07760558 COLORS-Validate Study of Decision-Support Software for Surgical Sequencing in Colorectal… | Not Yet Recruiting | |
| 2026-08-06 | NCT07749859 SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced… | Phase 2 | Not Yet Recruiting |
| 2026-08-04 | NCT07743749 An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors | Recruiting | |
| 2026-07-30 | NCT07735858 Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer | Active, Not Recruiting | |
| 2026-07-27 | NCT07729670 Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for… | Phase 2 | Not Yet Recruiting |
| 2026-07-24 | NCT07724223 Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC | Phase 2 | Recruiting |
| 2026-07-24 | NCT07725653 Impact of Anterior Urethral Suspension Combined With Pelvic Fascia Reconstruction During… | Completed | |
| 2026-07-22 | NCT07719738 Bevacizumab Plus Nab-paclitaxel and Tegafur Gimeracil Oteracil Potassium Capsule (S-1) as… | Phase 2 | Completed |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or… | Breast Cancer | Not Yet Recruiting |
| Phase 3 | |||
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of… | Thyroid Cancer | Recruiting |
| NCT06086457 | PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic… | Esophageal Neoplasms | Recruiting |
| NCT06757621 | Hypofractionated Postoperative Regional Nodal Irradiation for Patients With… | Breast Carcinoma | Recruiting |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC | Small-cell Lung Cancer | Recruiting |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT04821778 | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | Esophagus Cancer | Recruiting |
| NCT04821843 | Neoadjuvant Treatment Modalities in Esophageal Cancer | Esophageal Cancer | Recruiting |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC | Medullary Thyroid Carcinoma | Recruiting |
| NCT07443397 | Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. | Whole-Brain Radiotherapy | Recruiting |
| NCT07590024 | RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma (NPC) | Recruiting |
| NCT07084519 | Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction | Breast Cancer | Recruiting |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage… | Anal Squamous Cell Carcinoma, Limited-stage | Recruiting |
| NCT06149533 | Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis… | Thrombosis, Venous | Not Yet Recruiting |
| NCT06837597 | Jianzhong Qushi in Chronic RRI | Chronic Radiation Proctitis | Not Yet Recruiting |
| NCT07239271 | A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant… | Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy | Not Yet Recruiting |
| NCT04320979 | Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients | Breast Cancer | Active, Not Recruiting |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | Breast Cancer | Not Yet Recruiting |
| NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III… | NSCLC (Advanced Non-small Cell Lung Cancer) | Not Yet Recruiting |
| NCT07586657 | Precision Radiotherapy for Refractory Brain Metastases: A Multicenter Study | Brain Metastasases | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib… | HER2 Positive Breast Cancer | Recruiting |
| NCT05749289 | Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression | SSTR Positive Tumors | Recruiting |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and… | Triple-Negative Breast Cancer (TNBC) | Enrolling by Invitation |
| Phase 2 | |||
| NCT05762900 | Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk… | Breast Cancer | Recruiting |
| NCT05983107 | Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer | HR+/HER2- Advanced Breast Cancer | Recruiting |